Today's News & Views
November 8, 2007
 

Embryonic Stem Cell Ballot Referendum Defeated in New Jersey
Part One, Part two

Editor’s note. Please send me your thoughts at daveandrusko@hotmail.com.

 

In spite of seemingly enjoying every advantage, a New Jersey ballot referendum to authorize the state to borrow $450 million over 10 years to finance embryonic stem cell research went down to defeat Tuesday. Emphatically backed by Gov. Jon Corzine, "Question 2" lost 53% to 47%.

And while almost completely overlooked, the proposal--while purporting to ban research into human cloning-- in fact explicitly permitted research on cloned human embryos, as bioethicist Wesley Smith observed on his blog.   

Late last month, as opinion polls began to indicate a movement against Question 2, Corzine touted a study from Rutgers University that concluded when coupled with the $270 million stem-cell institute already authorized, passage of Question 2 "would generate $2.2 billion in economic benefit, 30,000 jobs and $115 million in state revenue."

Voters did not buy into Corzine's wildly optimistic arguments, and the defeat marked the first time New Jersey voters have rejected a statewide ballot initiative since 1990.

But the alleged economic payoff went hand-in-hand with Corzine's even less supportable insistence that "funding would help find cures for conditions such as spinal cord injuries, Parkinson's disease, sickle cell anemia and multiple sclerosis while also luring leading scientists and research firms to the state," according to the Associated Press.

Of course, all of that is hooey.

The defeat of Question 2 came about for any number of reasons, but it’s easy to share Wesley Smith’s assessment and enthusiasm.

 “Maybe CURES! CURES! CURES! is finally losing its political potency,” he wrote. “Maybe voters are finally seeing through the hype, obfuscation, and mendacity. And maybe, just maybe, this can lead to both ethical sanity and fiscal responsibility in biotechnology. In any event, whoopee!”

Please send your comments to Dave Andrusko at daveandrusko@hotmail.com.

Part Two